Zelira Therapeutics (AU:ZLD) has released an update.
Zelira Therapeutics Ltd reported a significant 556% increase in net losses, reaching (AUD $36,568,904) for the fiscal year ended June 30, 2024, compared to the previous year. Revenue also declined by 68%, and the company has not recommended or paid any dividends, reflecting a challenging financial period without any distribution reinvestment plans. Additionally, there were no changes in control over other entities, nor any associates or joint venture relationships established.
For further insights into AU:ZLD stock, check out TipRanks’ Stock Analysis page.
